Daiichi Sankyo Q311 Sales And Profit Drop

BMI View: Daiichi Sankyo needs to increase its exposure to both emerging markets and developed states. Despite the acceleration of Europe's sovereign debt crisis and the inevitability of further medicine price cuts, the Japanese company is under-represented in this multibillion dollar market and can still realise significant profit. In relation to non-traditional markets, the firm should fully leverage its majority stake in Ranbaxy Laboratories, which exports to over 100

To read the full article, please choose one of the following options: